title: Experimental osteodystrophy of chronic renal failure induced by aluminum- and ferric-nitrilotriacetate in Wistar rats.
abstract: The aluminum (AI) and iron (Fe) chelate complexes of nitrilotriacetate (NTA) cause renal insufficiency when they are administered intraperitoneally to rats. Their effects on bone metabolism were studied in 4 week old Wistar rats. Daily intraperitoneal administration of AI-NTA (3mg AI/kg for 11 weeks) induced osteomalacia, impaired bone growth, decreased bone mineral density, lower serum PTH levels than normal as well as renal insufficiency. Al staining showed diffuse deposition in the trabecula and a strong linear band of aluminum deposited at the mineralization front and along the cement line. The osteoid seen markedly within the trabecula was probably the decalcified portion of the bone, the calcium apatite of which was defectively fabricated because of diffuse Al deposition in the trabecula. Al deposition along the cement line would make it much more susceptible to external shear stress than normal. Although daily intraperitoneal administration of Fe-NTA (6 mg Fe/kg for 11 weeks) caused impaired bone growth, decreased bone mineral content and renal insufficiency, the osteoid volume did not increase. Fe staining showed that Fe was deposited diffusely in the cytoplasm of osteoblasts. The results of this study demonstrated that during renal insufficiency, different minerals exhibit different modes of action on bone metabolism, and that Al-NTA is useful for experimental animal models of Al-induced osteomalacia in renal insufficiency.
authors.affiliation: First Department of Pathology, Okayama University Medical School, Japan.
authors.forename: S
authors.initials: S
authors.lastname: Yukihiro
authors.forename: S
authors.initials: S
authors.lastname: Okada
authors.forename: K
authors.initials: K
authors.lastname: Takeuchi
authors.forename: H
authors.initials: H
authors.lastname: Inoue
mesh_terms: D000818:Animals; D012080:Chronic Kidney Disease-Mineral and Bone Disorder / Q000097:blood / Q000139:chemically induced* / Q000378:metabolism / Q000473:pathology; D005290:Ferric Compounds / Q000633:toxicity; D005452:Fluoresceins; D007668:Kidney / Q000187:drug effects; D008297:Male; D009571:Nitrilotriacetic Acid / Q000031:analogs & derivatives / Q000633:toxicity*; D051381:Rats; D017208:Rats, Wistar; D013977:Tibia / Q000378:metabolism / Q000473:pathology; D015430:Weight Gain / Q000187:drug effects
chemical_list: D005290:Ferric Compounds; D005452:Fluoresceins; D009571:Nitrilotriacetic Acid; C007740:fluorexon; C020326:ferric nitrilotriacetate